Pfizer Inc. (NYSE:PFE) Shares Acquired by James Investment Research Inc.

James Investment Research Inc. boosted its holdings in Pfizer Inc. (NYSE:PFE) by 30.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 41,592 shares of the biopharmaceutical company’s stock after purchasing an additional 9,712 shares during the quarter. James Investment Research Inc.’s holdings in Pfizer were worth $1,204,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Olistico Wealth LLC acquired a new stake in Pfizer during the second quarter worth about $25,000. MFA Wealth Advisors LLC acquired a new stake in shares of Pfizer during the 2nd quarter worth approximately $29,000. Quarry LP bought a new stake in shares of Pfizer in the 2nd quarter worth approximately $31,000. Financial Connections Group Inc. acquired a new position in Pfizer during the 2nd quarter valued at approximately $34,000. Finally, ESL Trust Services LLC acquired a new position in Pfizer during the 1st quarter valued at approximately $37,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Citigroup initiated coverage on shares of Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 price target for the company. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research note on Wednesday. Barclays boosted their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, Wells Fargo & Company boosted their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and a consensus target price of $33.58.

Pfizer Stock Down 0.8 %

PFE opened at $28.08 on Friday. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54. The business has a 50 day moving average of $29.03 and a 200-day moving average of $28.57. The stock has a market capitalization of $159.12 billion, a price-to-earnings ratio of 37.95, a P/E/G ratio of 0.90 and a beta of 0.67. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.40%. The business’s quarterly revenue was up 31.2% on a year-over-year basis. During the same period last year, the business posted ($0.17) EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.98%. Pfizer’s dividend payout ratio is currently 227.03%.

Insider Transactions at Pfizer

In other news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at $282,400. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.06% of the stock is owned by insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.